Latest Headlines

Latest Headlines

Collaborative KPI Therapeutics launches to beef up Kineta's pipeline

In a collaboration that will bring together service providers and CROs, newly launched KPI Therapeutics is aiming to speed the development of new drug candidates for Seattle-based biotech Kineta.

London's Institute of Cancer Research to help develop MRI-guided radiation systems

The Institute of Cancer Research, London, became the latest member of a consortium seeking to integrate magnetic resonance imaging into radiation therapy. 

Implantable glucose monitoring company Senseonics raises $20M

Senseonics has raised a $20 million venture round to get its implantable blood glucose monitor for diabetics through pivotal trials.

Boehringer's lung drug gets a boost from European regulators

Boehringer Ingelheim persuaded EU officials to put its lung-disease drug nintedanib on its development fast track, speeding its path to market as a treatment for idiopathic pulmonary fibrosis.

AbbVie readies production in anticipation of hep C treatment approval

AbbVie is awaiting the decisions of regulators for its closely followed new interferon-free, oral hepatitis C drug that will go head-to-head with Sovaldi. And it has lined up its production horses so that it will be ready to blast out of the gates if approvals are granted in the U.S. and Europe.

Syndax sets terms for a $69M IPO to support its 'breakthrough' drug

Syndax Pharmaceuticals is looking to raise $69 million in an IPO, planning to move 4.3 million shares at between $13 and $15 apiece.

GlaxoSmithKline tees up another huge cardio PhIII after darapladib flop

After a costly string of defeats with the heart drug darapladib, GlaxoSmithKline's cardio unit is rolling into Phase III with another cardiac hopeful, launching an expansive late-stage effort for losmapimod, designed to prevent repeat heart attacks.

The search is on for 2014's Fiercest biotech startups

Like we always do about this time of year, FierceBiotech is kicking off its search for the next class of Fierce 15 companies, and we want to hear from you. It's easy: Just fill out the form embedded below or find it here.

Halozyme soars after the FDA backs off of its cancer study

Halozyme is back on track with a midstage trial of its in-development pancreatic cancer treatment after the FDA lifted its clinical hold on enrollment, news that sent the company's shares up as much as 20%.

PharmAthene anthrax vax aces survival in rabbit study

PharmAthene's anthrax vaccine candidate, SparVax, works at least as well as currently licensed BioThrax from Emergent BioSolutions--at least, according to a study in New Zealand white rabbits.